Qube Research & Technologies (QRT)
TVTX icon

Qube Research & Technologies (QRT)’s Travere Therapeutics TVTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.9M Buy
669,159
+262,938
+65% +$7.86M 0.02% 889
2025
Q4 		$15.5M Sell
406,221
-165,776
-29% -$5.39M 0.02% 1056
2025
Q3 		$13.7M Sell
571,997
-32,131
-5% -$604K 0.01% 1124
2025
Q2 		$8.94M Buy
604,128
+311,137
+106% +$5.16M 0.01% 1360
2025
Q1 		$5.25M Buy
292,991
+244,954
+510% +$4.97M 0.01% 1501
2024
Q4 		$837K Buy
+48,037
New +$850K ﹤0.01% 2257
2024
Q2 		– Sell
-15,205
Closed -$117K – 4733
2024
Q1 		$117K Sell
15,205
-153,909
-91% -$1.3M ﹤0.01% 3241
2023
Q4 		$1.52M Buy
+169,114
New +$1.23M ﹤0.01% 1680
2022
Q4 		– Sell
-11,814
Closed -$291K – 3008
2022
Q3 		$291K Buy
+11,814
New +$305K ﹤0.01% 1637
2021
Q2 		– Sell
-38,125
Closed -$952K – 2806
2021
Q1 		$952K Buy
+38,125
New +$1.05M 0.02% 872
2020
Q3 		– Sell
-16,181
Closed -$330K – 2121
2020
Q2 		$330K Buy
+16,181
New +$258K ﹤0.01% 1257

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TVTX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Travere Therapeutics (TVTX) stake by 65% in Q1 2026, buying an estimated $7.86M and bringing the position to 669,159 shares worth $19.9M. The position accounts for 0.02% of the portfolio, ranked #889.

Qube Research & Technologies (QRT) first reported a position in TVTX in Q2 2020 and has held it in 11 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Qube Research & Technologies (QRT) held 669,159 shares of Travere Therapeutics worth $19.9M as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 262,938 Travere Therapeutics shares in Q1 2026, an estimated $7.86M.
  • Travere Therapeutics made up 0.02% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #889 holding.
  • Qube Research & Technologies (QRT) first reported a position in Travere Therapeutics in Q2 2020 and has held it in 11 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.